Literature DB >> 8590157

Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.

F Yamashita1, M Tanaka, S Satomura, K Tanikawa.   

Abstract

OBJECTIVE: To evaluate the value of lectin-reactive alpha-fetoprotein (LR-AFP) levels for assessing therapeutic effects and for predicting prognosis in patients with hepatocellular carcinoma (HCC) treated using transcatheter arterial embolization (TAE).
DESIGN: Twenty-nine patients with HCC were studied.
METHODS: LR-AFP levels were measured using lectin-affinity electrophoresis coupled with antibody-affinity blotting. Patients who were initially LR-AFP-positive were divided into those who became negative after TAE and those who remained positive. Patients were also classified into groups showing a reduction in total AFP levels of 75% or more and those showing a reduction of less than 75% and into groups whose tumour size was reduced by 50% or more and those whose tumour size was reduced by less than 50%.
RESULTS: Both the length of time between TAE and the recurrence of HCC and the cumulative survival rate differed significantly between the group of patients who became negative after TAE and that which remained positive. However, no significant differences in these parameters were found between the patients in the two classes for total AFP levels or tumour size.
CONCLUSIONS: LR-AFP levels appeared to be more useful for predicting clinical results than the serum total AFP value or changes in tumour size.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590157

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

2.  Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.

Authors:  R Kuromatsu; M Tanaka; Y Shimauchi; M Shimada; K Tanikawa; K Watanabe; T Yokoo
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis.

Authors:  A Nanashima; Y Sumida; S Tobinaga; K Shibata; H Shindo; M Obatake; S Shibasaki; N Ide; Takeshi Nagayasu
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

4.  Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.

Authors:  Brian I Carr; Futoshi Kanke; Margaret Wise; Shinji Satomura
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

Review 5.  Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Authors:  Massimiliano Berretta; Carla Cavaliere; Lara Alessandrini; Brigida Stanzione; Gaetano Facchini; Luca Balestreri; Tiziana Perin; Vincenzo Canzonieri
Journal:  Oncotarget       Date:  2017-02-21

Review 6.  Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.

Authors:  Ayman A Abdo; Mazen Hassanain; AbdulRahman AlJumah; Ashwaq Al Olayan; Faisal M Sanai; Hamad A Alsuhaibani; Huda Abdulkareem; Khalid Abdallah; Mohammad AlMuaikeel; Mohammad Al Saghier; Mohammad Babatin; Monther Kabbani; Shouki Bazarbashi; Peter Metrakos; Jordi Bruix
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.